JP2020527329A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527329A5
JP2020527329A5 JP2019567349A JP2019567349A JP2020527329A5 JP 2020527329 A5 JP2020527329 A5 JP 2020527329A5 JP 2019567349 A JP2019567349 A JP 2019567349A JP 2019567349 A JP2019567349 A JP 2019567349A JP 2020527329 A5 JP2020527329 A5 JP 2020527329A5
Authority
JP
Japan
Prior art keywords
b4galt1
nucleic acid
seq
sequence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019567349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527329A (ja
JP7661009B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/035806 external-priority patent/WO2018226560A1/en
Publication of JP2020527329A publication Critical patent/JP2020527329A/ja
Publication of JP2020527329A5 publication Critical patent/JP2020527329A5/ja
Priority to JP2023078115A priority Critical patent/JP2023113657A/ja
Application granted granted Critical
Publication of JP7661009B2 publication Critical patent/JP7661009B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019567349A 2017-06-05 2018-06-04 B4galt1バリアント及びその使用 Active JP7661009B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023078115A JP2023113657A (ja) 2017-06-05 2023-05-10 B4galt1バリアント及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762515140P 2017-06-05 2017-06-05
US62/515,140 2017-06-05
US201762550161P 2017-08-25 2017-08-25
US62/550,161 2017-08-25
US201862659344P 2018-04-18 2018-04-18
US62/659,344 2018-04-18
PCT/US2018/035806 WO2018226560A1 (en) 2017-06-05 2018-06-04 B4galt1 variants and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023078115A Division JP2023113657A (ja) 2017-06-05 2023-05-10 B4galt1バリアント及びその使用

Publications (3)

Publication Number Publication Date
JP2020527329A JP2020527329A (ja) 2020-09-10
JP2020527329A5 true JP2020527329A5 (enExample) 2021-07-26
JP7661009B2 JP7661009B2 (ja) 2025-04-14

Family

ID=62705750

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019567349A Active JP7661009B2 (ja) 2017-06-05 2018-06-04 B4galt1バリアント及びその使用
JP2023078115A Pending JP2023113657A (ja) 2017-06-05 2023-05-10 B4galt1バリアント及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023078115A Pending JP2023113657A (ja) 2017-06-05 2023-05-10 B4galt1バリアント及びその使用

Country Status (14)

Country Link
US (2) US10738284B2 (enExample)
EP (1) EP3635102B1 (enExample)
JP (2) JP7661009B2 (enExample)
KR (1) KR102624979B1 (enExample)
CN (1) CN110997906B (enExample)
AU (1) AU2018282072B2 (enExample)
CA (1) CA3065938A1 (enExample)
DK (1) DK3635102T3 (enExample)
ES (1) ES3049196T3 (enExample)
FI (1) FI3635102T3 (enExample)
IL (1) IL271073B2 (enExample)
MX (1) MX2019014661A (enExample)
SG (1) SG11201911597YA (enExample)
WO (1) WO2018226560A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738284B2 (en) 2017-06-05 2020-08-11 Regeneron Pharmaceuticals, Inc. B4GALT1 cDNA variants and compositions comprising the same
CN115279184A (zh) * 2020-03-04 2022-11-01 雷杰纳荣制药公司 B4galt1介导的功能的啮齿动物模型
CN120225673A (zh) 2022-06-01 2025-06-27 e-生物有限公司 表达和/或功能抑制剂
AU2023390632A1 (en) * 2022-12-09 2025-07-10 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
CN115960926A (zh) * 2022-12-30 2023-04-14 南方科技大学 一种mRNA及含有mRNA的药物
IL325863A (en) * 2023-07-27 2026-03-01 Tangram Therapeutics Plc Inhibitors of expression and/or function

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
CA2164288A1 (en) 1993-06-04 1994-12-22 Barbara Ensoli Method for treating kaposi's sarcoma with antisense oligonucleotides
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
EP0775204A1 (en) 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
CZ154898A3 (cs) 1995-11-21 1998-09-16 Icn Pharmaceuticals, Inc. Oligonukleotidy pro inhibici růstu nádorů zprostředkovaných IL-8 a receptorem IL-8
CN1215994A (zh) 1996-02-15 1999-05-05 国家健康学会 对治疗rsv感染有效的rna酶l激活剂和反义寡核苷酸
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
CA2248762A1 (en) 1997-10-22 1999-04-22 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of tnf-.alpha.
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
WO2003087341A2 (en) 2002-01-23 2003-10-23 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
WO2003080809A2 (en) 2002-03-21 2003-10-02 Sangamo Biosciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
US7374927B2 (en) 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
AU2005287278B2 (en) 2004-09-16 2011-08-04 Sangamo Biosciences, Inc. Compositions and methods for protein production
WO2009025645A1 (en) 2007-08-22 2009-02-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use
WO2009102820A2 (en) * 2008-02-11 2009-08-20 Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services Modified sugar substrates and methods of use
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
GB201000688D0 (en) * 2010-01-15 2010-03-03 Diagenic Asa Product and method
WO2011145121A1 (en) 2010-05-18 2011-11-24 Scatolificio Mogliani S.N.C. Di Mogliani Mauro E Andrea Cardboard box for stable stacking with other identical specimens
RU2444378C1 (ru) 2010-09-06 2012-03-10 Олег Германович Макеев Способ лечения коронарной недостаточности при моделируемой ишемии миокарда
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
PL3360964T3 (pl) 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
EP2922393B2 (en) 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases
CN112301024A (zh) 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US9267135B2 (en) 2013-06-04 2016-02-23 President And Fellows Of Harvard College RNA-guided transcriptional regulation
US10738284B2 (en) 2017-06-05 2020-08-11 Regeneron Pharmaceuticals, Inc. B4GALT1 cDNA variants and compositions comprising the same

Similar Documents

Publication Publication Date Title
JP2020527329A5 (enExample)
US7482141B2 (en) Methods and compositions for vitamin K epoxide reductase
Yu et al. Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease
WO2023055893A1 (en) Gene regulation
JP2008532544A (ja) 活性ビタミンk依存性タンパク質を生産するための方法及び組成物
CN106536753A (zh) 用于确定对mek/erk抑制剂的应答性的方法
KR101692545B1 (ko) 중증 아벨리노 각막이상증과 관련된 돌연변이 및 그 용도
CN104232650B (zh) 特发性基底节钙化新的致病基因及其编码蛋白质和应用
JP2022525545A5 (enExample)
JP2010515467A (ja) 心筋梗塞及び心不全における診断マーカー及び薬剤設計のためのプラットホーム
CA2677911C (en) Method of detecting equine polysaccharide storage myopathy
JP2024521224A (ja) 神経原性座位Notchホモログタンパク質3(NOTCH3)剤による脳血管疾患の治療
JP2022525546A5 (enExample)
RU2019144018A (ru) Варианты b4galt1 и их применение
KR102106807B1 (ko) 당뇨 망막증 진단용 마커 및 이의 용도
Tagaya et al. Novel alpha-fetoprotein-V messenger RNA isoforms in humans
Chen et al. Association of PCSK6 polymorphisms with susceptibility risk of large artery atherosclerotic stroke
JP4649163B2 (ja) 気管支喘息の遺伝的素因検査方法
CN121175436A (zh) 用压电式机械敏感离子通道组分1(piezo1)激动剂治疗静脉曲张
JP5111763B2 (ja) 気管支喘息の遺伝的素因検査方法
CN117795075A (zh) 使用溶质载剂家族27成员3(slc27a3)抑制剂治疗哮喘的方法
Xuelian Studies of common variations in two candidate genes of dyslipidemia and coronary artery disease
WO2019043201A1 (en) TRANSCRIPTION FACTOR ZNF471 USED AS THERAPEUTIC AGENT AND BIOMARKER
JP2004261067A (ja) フォンビルブランド因子切断酵素機能の検出方法
US20180369344A1 (en) Compositions and Methods for Treating Metabolic Disorders